Login to Your Account

Clean briefs: Acadia's pim slims risk of label warning; PDP advisory panel nears

By Randy Osborne
Staff Writer

Friday, March 25, 2016

With the release by the FDA of briefing documents Friday, any lingering investor frets eased about the fate of Acadia Pharmaceuticals Inc.'s Nuplazid (pimavanserin) for psychosis associated with Parkinson's disease (PDP) at Tuesday's advisory panel.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription